Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News CSL Ltd CMXHF

Healthcare Biotechnology
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (OTCQX:CMXHF)

Danish Medicines Council Grants Approval for CSL Behring's Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients

PR Newswire January 24, 2020

CSL Behring Launches Hizentra® Co-Pay Relief Program

PR Newswire May 20, 2014

New Findings Support Less Frequent Dosing in Hemophilia B Patients Treated with Coagulation Factor IX with Recombinant Albumin (rIX-FP)

PR Newswire May 11, 2014

CSL Opens World-Class, Advanced Manufacturing Facility for Late-Stage Production of Hemophilia Therapies Now in Development

PR Newswire May 9, 2014

CSL Behring Continues Commitment to Donate Bleeding Disorder Medications to World Federation of Hemophilia

PR Newswire April 17, 2014

CSL Behring Launches My Access(TM) Cost Share Program during Hemophilia Awareness Month

PR Newswire March 25, 2014

Patient Advocates And Social Workers Will Be Trained On Intricacies Of Affordable Care Act With CSL Behring Grant

PR Newswire March 24, 2014

First patient enrolled in phase III of COMPACT, a study of volume-reduced subcutaneous C1-INH for prevention of Hereditary Angioedema (HAE) attacks

PR Newswire February 20, 2014

CSL Behring and CSL Plasma Employees Open Their Hearts to Those in Need

PR Newswire February 20, 2014
View More News ››

Opinion & Analysis (OTCQX:CMXHF)

No current opinion is available.
View More Opinion ››

Bullboard Posts (OTCQX:CMXHF)

Be the first to post on this bullboard.

Nanalysis Scientific Corp.

Nanalysis Scientific Corp.

Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for ...
View More »